You just read:

FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

News provided by

CSL Behring

Mar 16, 2018, 08:00 ET